{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:36:30Z","timestamp":1791995790382,"version":"4.4.0"},"reference-count":142,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.prp.2024.155276","type":"journal-article","created":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T16:20:26Z","timestamp":1711815626000},"page":"155276","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Diagnostic performance of immunohistochemistry markers for malignant pleural mesothelioma diagnosis and subtypes. A systematic review and meta-analysis"],"prefix":"10.1016","volume":"257","author":[{"given":"Rafael","family":"Parra-Medina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pablo","family":"Casta\u00f1eda-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Chaves-Cabezas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pablo","family":"Alzate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jos\u00e9","family":"Chaves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2024.155276_bib1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00428-021-03031-7","article-title":"Pleural mesothelioma classification update","volume":"478","author":"Beasley","year":"2021","journal-title":"Virchows Arch."},{"key":"10.1016\/j.prp.2024.155276_bib2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.lungcan.2018.11.032","article-title":"Molecular pathways and diagnosis in malignant mesothelioma: a review of the 14th International Conference of the International Mesothelioma Interest Group","volume":"127","author":"Chapel","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.prp.2024.155276_bib3","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/PAS.0000000000001418","article-title":"Malignant diffuse mesothelioma in women","volume":"44","author":"Pavlisko","year":"2020","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.prp.2024.155276_bib4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jss.2015.01.043","article-title":"Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database","volume":"196","author":"Meyerhoff","year":"2015","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.prp.2024.155276_bib5","unstructured":"WHO Classification of Tumours Editorial, Thoracic Tumours WHO Classification of Tumours, 5th Edition, Volume 5, 2021."},{"key":"10.1016\/j.prp.2024.155276_bib6","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.3390\/jcm10112434","article-title":"When the diagnosis of mesothelioma challenges textbooks and guidelines","volume":"10","author":"Rossi","year":"2021","journal-title":"J. Clin. Med"},{"key":"10.1016\/j.prp.2024.155276_bib7","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.5858\/arpa.2012-0112-RA","article-title":"The separation of benign and malignant mesothelial proliferations","volume":"136","author":"Churg","year":"2012","journal-title":"Arch. Pathol. Lab Med"},{"key":"10.1016\/j.prp.2024.155276_bib8","doi-asserted-by":"crossref","first-page":"318","DOI":"10.5858\/arpa.2015-0240-SA","article-title":"New Markers for Separating Benign From Malignant Mesothelial Proliferations: are we there yet?","volume":"140","author":"Churg","year":"2016","journal-title":"Arch. Pathol. Lab Med"},{"key":"10.1016\/j.prp.2024.155276_bib9","doi-asserted-by":"crossref","first-page":"S353","DOI":"10.21037\/jtd.2017.10.132","article-title":"Serum mesothelin and other biomarkers: what have we learned in the last decade?","volume":"10","author":"Cristaudo","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.prp.2024.155276_bib10","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.21037\/tlcr.2019.11.29","article-title":"Application of immunohistochemistry in diagnosis and management of malignant mesothelioma","volume":"9","author":"Chapel","year":"2020","journal-title":"Transl. Lung Cancer Res"},{"key":"10.1016\/j.prp.2024.155276_bib11","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/pin.13235","article-title":"Update of pathological diagnosis of pleural mesothelioma using genomic-based morphological techniques, for both histological and cytological investigations","volume":"72","author":"Nabeshima","year":"2022","journal-title":"Pathol. Int."},{"key":"10.1016\/j.prp.2024.155276_bib12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst. Rev."},{"key":"10.1016\/j.prp.2024.155276_bib13","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann. Intern Med"},{"key":"10.1016\/j.prp.2024.155276_bib14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/01.NAJ.0000451683.66447.89","article-title":"JBI\u2019s Systematic Reviews","volume":"114","author":"Munn","year":"2014","journal-title":"AJN, Am. J. Nurs."},{"key":"10.1016\/j.prp.2024.155276_bib15","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/BF00713385","article-title":"Immunohistochemistry in the diagnosis of malignant mesothelioma","volume":"411","author":"Pfaltz","year":"1987","journal-title":"Virchows Arch. A Pathol. Anat. Histopathol."},{"key":"10.1016\/j.prp.2024.155276_bib16","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S0344-0338(11)80900-3","article-title":"The value of immunohistochemistry of pleural biopsy specimens in the differential diagnosis between malignant mesothelioma and metastatic carcinoma","volume":"190","author":"Grove","year":"1994","journal-title":"Pathol. Res Pr."},{"key":"10.1016\/j.prp.2024.155276_bib17","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/jcp.50.10.859","article-title":"HBME-1 and antithrombomodulin in the differential diagnosis of malignant mesothelioma of pleura","volume":"50","author":"Kennedy","year":"1997","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.prp.2024.155276_bib18","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1046\/j.1365-2559.1996.d01-562.x","article-title":"Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME-1 expression","volume":"30","author":"Bateman","year":"1997","journal-title":"Histopathology"},{"key":"10.1016\/j.prp.2024.155276_bib19","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1046\/j.1365-2559.1997.d01-590.x","article-title":"CD44H expression in reactive mesothelium, pleural mesothelioma and pulmonary adenocarcinoma","volume":"30","author":"Attanoos","year":"1997","journal-title":"Histopathology"},{"key":"10.1016\/j.prp.2024.155276_bib20","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0304-3835(97)00466-7","article-title":"TTF-1 protein expression in pleural malignant mesotheliomas and adenocarcinomas of the lung","volume":"124","author":"Di Loreto","year":"1998","journal-title":"Cancer Lett."},{"key":"10.1016\/j.prp.2024.155276_bib21","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1046\/j.1365-2559.2000.00770.x","article-title":"HBME-1, MOC-31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma","volume":"36","author":"Oates","year":"2000","journal-title":"Histopathology"},{"key":"10.1016\/j.prp.2024.155276_bib22","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1046\/j.1365-2559.2001.01157.x","article-title":"Combined use of novel epithelial (MOC-31) and mesothelial (HBME-1) immunohistochemical markers for optimal first line diagnostic distinction between mesothelioma and metastatic carcinoma in pleura","volume":"38","author":"Gonz\u00e1lez-Lois","year":"2001","journal-title":"Histopathology"},{"key":"10.1016\/j.prp.2024.155276_bib23","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/modpathol.3800027","article-title":"Diagnostic value of MUC4 immunostaining in distinguishing epithelial mesothelioma and lung adenocarcinoma","volume":"17","author":"Llinares","year":"2004","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.prp.2024.155276_bib24","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/modpathol.3800259","article-title":"Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma","volume":"18","author":"Chu","year":"2005","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.prp.2024.155276_bib25","first-page":"205","article-title":"Expression of mesothelial markers in malignant mesotheliomas: an immunohistochemical evaluation of 173 cases","volume":"55","author":"Soomro","year":"2005","journal-title":"J. Pak. Med Assoc."},{"key":"10.1016\/j.prp.2024.155276_bib26","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/00000478-200604000-00006","article-title":"h-Caldesmon, a useful positive marker in the diagnosis of pleural malignant mesothelioma, epithelioid type","volume":"30","author":"Comin","year":"2006","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.prp.2024.155276_bib27","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1309\/BME4VG11LDX8KMTN","article-title":"Immunohistochemical expression of osteopontin in epithelioid mesotheliomas and reactive mesothelial proliferations","volume":"127","author":"Tigrani","year":"2007","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.prp.2024.155276_bib28","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1365-2559.2007.02743.x","article-title":"Claudin-4 in mesothelioma diagnosis","volume":"51","author":"Facchetti","year":"2007","journal-title":"Histopathology"},{"key":"10.1016\/j.prp.2024.155276_bib29","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1440-1827.2007.02080.x","article-title":"Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma","volume":"57","author":"Kushitani","year":"2007","journal-title":"Pathol. Int"},{"key":"10.1016\/j.prp.2024.155276_bib30","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/cncr.22477","article-title":"Novel marker D2-40, combined with calretinin, CEA, and TTF-1","volume":"109","author":"Mimura","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.prp.2024.155276_bib31","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/modpathol.3800732","article-title":"Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma","volume":"20","author":"Kato","year":"2007","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.prp.2024.155276_bib32","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/PAS.0b013e31814faacf","article-title":"Podoplanin is a better immunohistochemical marker for sarcomatoid mesothelioma than calretinin","volume":"32","author":"Padgett","year":"2008","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.prp.2024.155276_bib33","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1365-2559.2009.03322.x","article-title":"Caveolin-1 is a novel immunohistochemical marker to differentiate epithelioid mesothelioma from lung adenocarcinoma","volume":"55","author":"Amatya","year":"2009","journal-title":"Histopathology"},{"key":"10.1016\/j.prp.2024.155276_bib34","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.athoracsur.2009.04.038","article-title":"Placenta growth factor expression has prognostic value in malignant pleural mesothelioma","volume":"88","author":"Pompeo","year":"2009","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.prp.2024.155276_bib35","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.prp.2009.06.001","article-title":"Is D2-40 a useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations?","volume":"205","author":"Deniz","year":"2009","journal-title":"Pathol. Res. Pr."},{"key":"10.1016\/j.prp.2024.155276_bib36","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1440-1827.2009.02404.x","article-title":"Malignant pleural mesothelioma: clinicopathology of 16 extrapleural pneumonectomy patients with special reference to early stage features","volume":"59","author":"Hiroshima","year":"2009","journal-title":"Pathol. Int"},{"key":"10.1016\/j.prp.2024.155276_bib37","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/jcp.2008.060533","article-title":"Expression of GATA-6 transcription factor in pleural malignant mesothelioma and metastatic pulmonary adenocarcinoma","volume":"62","author":"Lindholm","year":"2009","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.prp.2024.155276_bib38","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/j.1365-2559.2009.03298.x","article-title":"Value of immunohistochemistry in the differential diagnosis of pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma","volume":"54","author":"Takeshima","year":"2009","journal-title":"Histopathology"},{"key":"10.1016\/j.prp.2024.155276_bib39","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00428-010-0975-8","article-title":"TLE1 expression in malignant mesothelioma","volume":"457","author":"Matsuyama","year":"2010","journal-title":"Virchows Arch."},{"key":"10.1016\/j.prp.2024.155276_bib40","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1177\/147323001003800334","article-title":"The diagnostic utility of maspin in the distinction between malignant mesothelioma and pulmonary adenocarcinoma","volume":"38","author":"Akyildiz","year":"2010","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.prp.2024.155276_bib41","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1309\/AJCPP5R2ZJZKCLWN","article-title":"The diagnostic utility of p16 fish and GLUT-1 immunohistochemical analysis in mesothelial proliferations","volume":"135","author":"Monaco","year":"2011","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.prp.2024.155276_bib42","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1097\/PAS.0b013e318218985b","article-title":"Oncofetal Protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation","volume":"35","author":"Shi","year":"2011","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.prp.2024.155276_bib43","first-page":"742","article-title":"\u03b2-catenin expression in benign and malignant pleural disorders","volume":"4","author":"Anani","year":"2011","journal-title":"Int J. Clin. Exp. Pathol."},{"key":"10.1016\/j.prp.2024.155276_bib44","doi-asserted-by":"crossref","first-page":"804","DOI":"10.5858\/arpa.2011-0219-OA","article-title":"Utility of Glucose Transporter 1 in the distinction of benign and malignant thoracic and abdominal mesothelial lesions","volume":"136","author":"Lagana","year":"2012","journal-title":"Arch. Pathol. Lab Med"},{"key":"10.1016\/j.prp.2024.155276_bib45","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/dc.22821","article-title":"CD147 immunohistochemistry discriminates between reactive mesothelial cells and malignant mesothelioma","volume":"40","author":"Pinheiro","year":"2012","journal-title":"Diagn. Cytopathol."},{"key":"10.1016\/j.prp.2024.155276_bib46","doi-asserted-by":"crossref","first-page":"E96","DOI":"10.1111\/j.1365-2559.2012.04196.x","article-title":"The diagnostic value of immunohistochemically detected methylthioadenosine phosphorylase deficiency in malignant pleural mesotheliomas","volume":"60","author":"Zimling","year":"2012","journal-title":"Histopathology"},{"key":"10.1016\/j.prp.2024.155276_bib47","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00428-012-1344-6","article-title":"Expression and role of GLUT-1, MCT-1, and MCT-4 in malignant pleural mesothelioma","volume":"462","author":"Mogi","year":"2013","journal-title":"Virchows Arch."},{"key":"10.1016\/j.prp.2024.155276_bib48","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1136\/jclinpath-2012-201020","article-title":"CD24: a potential new marker in differentiating malignant mesothelioma from pulmonary adenocarcinoma","volume":"66","author":"Pinato","year":"2013","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.prp.2024.155276_bib49","first-page":"663","article-title":"Immunohistochemistry of cytokeratins 7, 8, 17, 18, and 19, and GLUT-1 aids differentiation of desmoplastic malignant mesothelioma from fibrous pleuritis","volume":"28","author":"Horiuchi","year":"2013","journal-title":"Histol. Histopathol."},{"key":"10.1016\/j.prp.2024.155276_bib50","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1309\/AJCPM2Z4NGIIPBGE","article-title":"CD90 is a diagnostic marker to differentiate between malignant pleural mesothelioma and lung carcinoma with immunohistochemistry","volume":"140","author":"Kawamura","year":"2013","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.prp.2024.155276_bib51","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/PAS.0b013e31826ab1c0","article-title":"IMP3 and GLUT-1 Immunohistochemistry for distinguishing benign from malignant mesothelial proliferations","volume":"37","author":"Lee","year":"2013","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.prp.2024.155276_bib52","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1177\/1066896913491320","article-title":"Claudin-4 as a marker for distinguishing malignant mesothelioma from lung carcinoma and serous adenocarcinoma","volume":"21","author":"Ohta","year":"2013","journal-title":"Int J. Surg. Pathol."},{"key":"10.1016\/j.prp.2024.155276_bib53","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.2298\/VSP110527025P","article-title":"The role of immunohistochemical evaluation in the diagnosis of malignant mesothelioma of the pleura","volume":"70","author":"Panjkovic","year":"2013","journal-title":"Vojn. Pregl."},{"key":"10.1016\/j.prp.2024.155276_bib54","doi-asserted-by":"crossref","first-page":"94","DOI":"10.5146\/tjpath.2013.01158","article-title":"Value of glut-1 and koc markers in the differential diagnosis of reactive mesothelial hyperplasia, malignant mesothelioma and pulmonary adenocarcinoma","volume":"29","author":"Ucer","year":"2013","journal-title":"Turk. J. Pathol."},{"key":"10.1016\/j.prp.2024.155276_bib55","first-page":"451","article-title":"Expression of glucose transporter protein 1 and desmin in reactive mesothelial hyperplasia and epithelioid malignant mesothelioma, Chinese","volume":"42","author":"Wei","year":"2013","journal-title":"J. Pathol."},{"key":"10.1016\/j.prp.2024.155276_bib56","doi-asserted-by":"crossref","first-page":"161","DOI":"10.4149\/neo_2014_031","article-title":"Expression of carbonic anhydrase IX (CAIX) in malignant mesothelioma. An immunohistochemical and immunocytochemical study","volume":"61","author":"Capkova","year":"2014","journal-title":"Neoplasma"},{"key":"10.1016\/j.prp.2024.155276_bib57","first-page":"559","article-title":"Expression of thrombomodulin, calretinin, cytokeratin 5\/6, D2-40 and WT-1 in a series of primary carcinomas of the lung: an immunohistochemical study in comparison with epithelioid pleural mesothelioma","volume":"100","author":"Comin","year":"2014","journal-title":"Tumori"},{"key":"10.1016\/j.prp.2024.155276_bib58","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/pin.12216","article-title":"Practical utility of insulin-like growth factor II mRNA-binding protein 3, glucose transporter 1, and epithelial membrane antigen for distinguishing malignant mesotheliomas from benign mesothelial proliferations","author":"Chang","year":"2014","journal-title":"Pathol. Int."},{"key":"10.1016\/j.prp.2024.155276_bib59","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.lungcan.2013.12.009","article-title":"How useful is GLUT-1 in differentiating mesothelial hyperplasia and fibrosing pleuritis from epithelioid and sarcomatoid mesotheliomas? An international collaborative study","volume":"83","author":"Husain","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.prp.2024.155276_bib60","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1309\/AJCP5KNL7QTELLYI","article-title":"Comparative immunohistochemical Analysis of IMP3, GLUT1, EMA, CD146, and desmin for distinguishing malignant mesothelioma from reactive mesothelial cells","volume":"141","author":"Minato","year":"2014","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.prp.2024.155276_bib61","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.humpath.2014.03.006","article-title":"Diagnostic utility of immunohistochemistry in distinguishing between epithelioid pleural mesotheliomas and breast carcinomas: a comparative study","volume":"45","author":"Ord\u00f3\u00f1ez","year":"2014","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.prp.2024.155276_bib62","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/modpathol.2015.65","article-title":"BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations","volume":"28","author":"Cigognetti","year":"2015","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.prp.2024.155276_bib63","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/PAT.0000000000000250","article-title":"Loss of expression of BAP1 predicts longer survival in mesothelioma","volume":"47","author":"Farzin","year":"2015","journal-title":"Pathology"},{"key":"10.1016\/j.prp.2024.155276_bib64","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.humpath.2015.06.024","article-title":"BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma","volume":"46","author":"McGregor","year":"2015","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.prp.2024.155276_bib65","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","article-title":"High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma","volume":"10","author":"Nasu","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.prp.2024.155276_bib66","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.prp.2016.07.010","article-title":"Pathology reporting of malignant pleural mesothelioma first diagnosis: a population-based approach","volume":"212","author":"Ascoli","year":"2016","journal-title":"Pathol. Res Pr."},{"key":"10.1016\/j.prp.2024.155276_bib67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.anndiagpath.2016.04.007","article-title":"c-Met expression and MET amplification in malignant pleural mesothelioma","volume":"23","author":"Bois","year":"2016","journal-title":"Ann. Diagn. Pathol."},{"key":"10.1016\/j.prp.2024.155276_bib68","doi-asserted-by":"crossref","first-page":"59314","DOI":"10.18632\/oncotarget.10653","article-title":"Positive nuclear BAP1 immunostaining helps differentiate non-small cell lung carcinomas from malignant mesothelioma","volume":"7","author":"Carbone","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2024.155276_bib69","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1097\/01.PAT.0000461535.76696.50","article-title":"Comparison of performance profiles of TTF1 antibodies for differential diagnosis","volume":"47","author":"Swalling","year":"2016","journal-title":"Pathology"},{"key":"10.1016\/j.prp.2024.155276_bib70","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000442092","article-title":"Use of anti-noxa antibody for differential diagnosis between epithelioid mesothelioma and reactive mesothelial hyperplasia","volume":"83","author":"Kushitani","year":"2016","journal-title":"Pathobiology"},{"key":"10.1016\/j.prp.2024.155276_bib71","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/j.jtho.2016.06.020","article-title":"BRCA1-Associated Protein 1 (BAP1) immunohistochemical expression as a diagnostic tool in malignant pleural mesothelioma classification: a large retrospective study","volume":"11","author":"Righi","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.prp.2024.155276_bib72","doi-asserted-by":"crossref","DOI":"10.5858\/arpa.2015-0508-LE","article-title":"Immunohistochemistry for NF2, LATS1\/2, and YAP\/TAZ fails to separate benign from malignant mesothelial proliferations","volume":"140","author":"Sheffield","year":"2016","journal-title":"Arch. Pathol. Lab Med"},{"key":"10.1016\/j.prp.2024.155276_bib73","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.pathol.2016.08.003","article-title":"Calretinin but not caveolin-1 correlates with tumour histology and survival in malignant mesothelioma","volume":"48","author":"Thapa","year":"2016","journal-title":"Pathology"},{"key":"10.1016\/j.prp.2024.155276_bib74","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/his.13123","article-title":"Diagnostic utility of BAP1 and EZH2 expression in malignant mesothelioma","volume":"70","author":"Shinozaki-Ushiku","year":"2017","journal-title":"Histopathology"},{"key":"10.1016\/j.prp.2024.155276_bib75","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1097\/PAS.0000000000000825","article-title":"GATA3 Immunohistochemistry for distinguishing sarcomatoid and desmoplastic mesothelioma from sarcomatoid carcinoma of the lung","volume":"41","author":"Berg","year":"2017","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.prp.2024.155276_bib76","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.lungcan.2016.12.017","article-title":"Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: comparison with 9p21 FISH and BAP1 immunohistochemistry","volume":"104","author":"Hida","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.prp.2024.155276_bib77","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1097\/PAS.0000000000000852","article-title":"Identification of DAB2 and Intelectin-1 as novel positive immunohistochemical markers of epithelioid mesothelioma by transcriptome microarray analysis for its differentiation from pulmonary adenocarcinoma","volume":"41","author":"Kuraoka","year":"2017","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.prp.2024.155276_bib78","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.humpath.2017.07.015","article-title":"The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell\/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center","volume":"67","author":"Marchevsky","year":"2017","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.prp.2024.155276_bib79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/1310478","article-title":"Malignant mesothelioma, BAP1 immunohistochemistry, and VEGFA: does BAP1 have potential for early diagnosis and assessment of prognosis?","volume":"2017","author":"Pulford","year":"2017","journal-title":"Dis. Markers"},{"key":"10.1016\/j.prp.2024.155276_bib80","doi-asserted-by":"crossref","DOI":"10.1038\/srep45768","article-title":"HEG1 is a novel mucin-like membrane protein that serves as a diagnostic and therapeutic target for malignant mesothelioma","volume":"7","author":"Tsuji","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.prp.2024.155276_bib81","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.anndiagpath.2016.10.010","article-title":"Usefulness of p16\/CDKN2A fluorescence in situ hybridization and BAP1 immunohistochemistry for the diagnosis of biphasic mesothelioma","volume":"26","author":"Wu","year":"2017","journal-title":"Ann. Diagn. Pathol."},{"key":"10.1016\/j.prp.2024.155276_bib82","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/modpathol.2017.190","article-title":"Glypican-1 immunohistochemistry is a novel marker to differentiate epithelioid mesothelioma from lung adenocarcinoma","volume":"31","author":"Amatya","year":"2018","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.prp.2024.155276_bib83","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/s41379-018-0066-y","article-title":"Glypican-1 immunohistochemistry does not separate mesothelioma from pulmonary adenocarcinoma","volume":"31","author":"Chiu","year":"2018","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.prp.2024.155276_bib84","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.pathol.2018.05.002","article-title":"Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications","volume":"50","author":"Forest","year":"2018","journal-title":"Pathology"},{"key":"10.1016\/j.prp.2024.155276_bib85","doi-asserted-by":"crossref","first-page":"190","DOI":"10.4103\/ijc.IJC_584_17","article-title":"Malignant mesothelioma: a histomorphological and immunohistochemical study of 24 cases from a tertiary care hospital in Southern India","volume":"55","author":"Hui","year":"2018","journal-title":"Indian J. Cancer"},{"key":"10.1016\/j.prp.2024.155276_bib86","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/cncy.21928","article-title":"A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma","volume":"126","author":"Kinoshita","year":"2018","journal-title":"Cancer Cytopathol."},{"key":"10.1016\/j.prp.2024.155276_bib87","first-page":"3540","article-title":"Utility of Survivin, BAP1, and Ki-67 immunohistochemistry in distinguishing epithelioid mesothelioma from reactive mesothelial hyperplasia","author":"Kushitani","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.prp.2024.155276_bib88","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41598-017-18545-x","article-title":"MUC4 immunohistochemistry is useful in distinguishing epithelioid mesothelioma from adenocarcinoma and squamous cell carcinoma of the lung","volume":"8","author":"Mawas","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.prp.2024.155276_bib89","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/his.13775","article-title":"Mucin 21 is a novel, negative immunohistochemical marker for epithelioid mesothelioma for its differentiation from lung adenocarcinoma","volume":"74","author":"Kai","year":"2019","journal-title":"Histopathology"},{"key":"10.1016\/j.prp.2024.155276_bib90","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.lungcan.2018.12.004","article-title":"Retrospective response analysis of BAP1 expression to predict the clinical activity of systemic cytotoxic chemotherapy in mesothelioma","volume":"127","author":"Kumar","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.prp.2024.155276_bib91","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/cyt.12738","article-title":"Diagnostic value of BRCA1-associated protein-1, glucose transporter-1 and desmin expression in the discrimination between reactive mesothelial proliferation and malignant mesothelioma in tissues and effusions","volume":"30","author":"\u00d6nder","year":"2019","journal-title":"Cytopathology"},{"key":"10.1016\/j.prp.2024.155276_bib92","first-page":"1060","article-title":"A gene-expression-based test can outperform bap1 and p16 analyses in the differential diagnosis of pleural mesothelial proliferations","author":"Ali","year":"2019","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.prp.2024.155276_bib93","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1007\/s12253-019-00751-9","article-title":"Monoclonal caveolin 1 expression in the differential diagnosis of malignant pleural mesothelioma and pulmonary adenocarcinoma: Is it Useful?","volume":"26","author":"Bozdag","year":"2020","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.prp.2024.155276_bib94","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41379-019-0411-9","article-title":"Cyclin D1 immunohistochemical staining to separate benign from malignant mesothelial proliferations","volume":"33","author":"Pors","year":"2020","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.prp.2024.155276_bib95","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/cncy.22221","article-title":"Usefulness of methylthioadenosine phosphorylase and BRCA-associated protein 1 immunohistochemistry in the diagnosis of malignant mesothelioma in effusion cytology specimens","volume":"128","author":"Berg","year":"2020","journal-title":"Cancer Cytopathol."},{"key":"10.1016\/j.prp.2024.155276_bib96","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.lungcan.2020.06.024","article-title":"Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: a single center experience with systematic review and meta-analysis","volume":"146","author":"Cantini","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.prp.2024.155276_bib97","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1097\/PAS.0000000000001507","article-title":"SOX6 is a novel immunohistochemical marker for differential diagnosis of epithelioid mesothelioma from lung adenocarcinoma","volume":"44","author":"Kambara","year":"2020","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.prp.2024.155276_bib98","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.humpath.2020.04.005","article-title":"Claudin-4 shows superior specificity for mesothelioma vs non\u2013small-cell lung carcinoma compared with MOC-31 and Ber-EP4","volume":"100","author":"Naso","year":"2020","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.prp.2024.155276_bib99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2020.08.005","article-title":"The potential utility of GATA binding protein 3 for diagnosis of malignant pleural mesotheliomas","volume":"105","author":"Prabhakaran","year":"2020","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.prp.2024.155276_bib100","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.humpath.2020.08.010","article-title":"c-MET immunohistochemistry for differentiating malignant mesothelioma from benign mesothelial proliferations","volume":"105","author":"Ren","year":"2020","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.prp.2024.155276_bib101","article-title":"Sarcomatoid mesothelioma: a CDKN2A molecular analysis of 53 cases with immunohistochemical correlation with BAP1","volume":"216","author":"Zaleski","year":"2020","journal-title":"Pathol. Res Pr."},{"key":"10.1016\/j.prp.2024.155276_bib102","first-page":"3871","article-title":"Survivin expression as an independent predictor of overall survival in malignant peritoneal mesothelioma","author":"Zhang","year":"2020","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.prp.2024.155276_bib103","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/path.5551","article-title":"Large-scale analysis of <scp>BAP1<\/scp> expression reveals novel associations with clinical and molecular features of malignant pleural mesothelioma","volume":"253","author":"De Rienzo","year":"2021","journal-title":"J. Pathol."},{"key":"10.1016\/j.prp.2024.155276_bib104","doi-asserted-by":"crossref","DOI":"10.3389\/pore.2021.600073","article-title":"Diagnostic Utility of BAP1, EZH2 and Survivin in differentiating pleural epithelioid mesothelioma and reactive mesothelial hyperplasia: immunohistochemical study","volume":"27","author":"Hakim","year":"2021","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.prp.2024.155276_bib105","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/pin.13140","article-title":"Membranous HEG1 expression is a useful marker in the differential diagnosis of epithelioid and biphasic malignant mesothelioma versus carcinomas","volume":"71","author":"Hiroshima","year":"2021","journal-title":"Pathol. Int."},{"key":"10.1016\/j.prp.2024.155276_bib106","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1097\/PAS.0000000000001712","article-title":"Utility of SOX6 and DAB2 for the diagnosis of malignant mesothelioma","volume":"45","author":"Naso","year":"2021","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.prp.2024.155276_bib107","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1177\/10668969211014256","article-title":"Sarcomatoid Mesothelioma: a Clinicopathological and Immunohistochemical Study of 64 Cases","volume":"29","author":"Oramas","year":"2021","journal-title":"Int J. Surg. Pathol."},{"key":"10.1016\/j.prp.2024.155276_bib108","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00428-021-03048-y","article-title":"GATA3 is a useful immunohistochemical marker for distinguishing sarcomatoid malignant mesothelioma from lung sarcomatoid carcinoma and organizing pleuritis","volume":"479","author":"Piao","year":"2021","journal-title":"Virchows Arch."},{"key":"10.1016\/j.prp.2024.155276_bib109","doi-asserted-by":"crossref","first-page":"12868","DOI":"10.3390\/ijms222312868","article-title":"Correlation of MET-Receptor Overexpression with MET gene amplification and patient outcome in malignant mesothelioma","volume":"22","author":"Santoni-Rugiu","year":"2021","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.prp.2024.155276_bib110","doi-asserted-by":"crossref","first-page":"208","DOI":"10.5858\/arpa.2019-0647-OA","article-title":"Utility of immunohistochemistry for MUC4 and GATA3 to Aid in the distinction of pleural sarcomatoid mesothelioma from pulmonary sarcomatoid carcinoma","volume":"145","author":"Terra","year":"2021","journal-title":"Arch. Pathol. Lab Med"},{"key":"10.1016\/j.prp.2024.155276_bib111","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/s41379-022-01081-z","article-title":"Clinical and molecular validation of BAP1, MTAP, P53, and Merlin immunohistochemistry in diagnosis of pleural mesothelioma","volume":"35","author":"Chapel","year":"2022","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.prp.2024.155276_bib112","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-20334-0","article-title":"RhoA and vigilin are candidates for immunohistochemical markers for epithelioid malignant mesothelioma","volume":"12","author":"Hiratsuka","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.prp.2024.155276_bib113","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jasc.2022.07.003","article-title":"Diagnostic capacity of BAP1 and MTAP in cytology from effusions and biopsy in mesothelioma","volume":"11","author":"Lyngg\u00e5rd","year":"2022","journal-title":"J. Am. Soc. Cytopathol."},{"key":"10.1016\/j.prp.2024.155276_bib114","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/ajcp\/aqac022","article-title":"Usefulness of Cyclin D1\/Podoplanin dual immunohistochemical stain to differentiate malignant mesothelioma from reactive mesothelial proliferations","volume":"158","author":"Pillappa","year":"2022","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.prp.2024.155276_bib115","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/ajcp\/aqab091","article-title":"Loss of methylthioadenosine phosphorylase by immunohistochemistry is common in pulmonary sarcomatoid carcinoma and sarcomatoid mesothelioma","volume":"157","author":"Terra","year":"2022","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.prp.2024.155276_bib116","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3892\/br.2022.1549","article-title":"Clinical significance of 9P21 gene combined with BAP1 and MTAP protein expression in diagnosis and prognosis of mesothelioma serous effusion","volume":"17","author":"Ma","year":"2022","journal-title":"Biomed. Rep."},{"key":"10.1016\/j.prp.2024.155276_bib117","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3390\/diagnostics13020249","article-title":"Immunohistochemistry for Claudin-4 and BAP1 in the differential diagnosis between sarcomatoid carcinoma and sarcomatoid mesothelioma","volume":"13","author":"Zuccatosta","year":"2023","journal-title":"Diagnostics"},{"key":"10.1016\/j.prp.2024.155276_bib118","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/s41379-018-0159-7","article-title":"Immunohistochemical evaluation of nuclear 5-hydroxymethylcytosine (5-hmC) accurately distinguishes malignant pleural mesothelioma from benign mesothelial proliferations","volume":"32","author":"Chapel","year":"2019","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.prp.2024.155276_bib119","doi-asserted-by":"crossref","first-page":"924","DOI":"10.21037\/tlcr.2020.03.38","article-title":"Clinical significance of histologic subtyping of malignant pleural mesothelioma","volume":"9","author":"Brcic","year":"2020","journal-title":"Transl. Lung Cancer Res"},{"key":"10.1016\/j.prp.2024.155276_bib120","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1073\/pnas.1309085110","article-title":"Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair","volume":"111","author":"Yu","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.prp.2024.155276_bib121","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jtho.2022.04.008","article-title":"BAP1 Loss by Immunohistochemistry Predicts Improved survival to first-line platinum and pemetrexed chemotherapy for patients with pleural mesothelioma: a validation study","volume":"17","author":"Louw","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.prp.2024.155276_bib122","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrc3459","article-title":"BAP1 and cancer","volume":"13","author":"Carbone","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.prp.2024.155276_bib123","doi-asserted-by":"crossref","first-page":"68863","DOI":"10.18632\/oncotarget.20317","article-title":"Diagnostic accuracy of BRCA1-associated protein 1 in malignant mesothelioma: a meta-analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2024.155276_bib124","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/cncy.22509","article-title":"Evidence-based diagnostic performance of novel biomarkers for the diagnosis of malignant mesothelioma in effusion cytology","volume":"130","author":"Girolami","year":"2022","journal-title":"Cancer Cytopathol."},{"key":"10.1016\/j.prp.2024.155276_bib125","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/gcc.22218","article-title":"Inference on germline BAP1 mutations and asbestos exposure from the analysis of familial and sporadic mesothelioma in a high-risk area","volume":"54","author":"Betti","year":"2015","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.prp.2024.155276_bib126","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/PAT.0b013e32835d0efb","article-title":"Tumours associated with BAP1 mutations","volume":"45","author":"Murali","year":"2013","journal-title":"Pathology"},{"issue":"1979","key":"10.1016\/j.prp.2024.155276_bib127","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1126\/science.aad5944","article-title":"Disordered methionine metabolism in MTAP\/CDKN2A-deleted cancers leads to dependence on PRMT5","volume":"351","author":"Mavrakis","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.prp.2024.155276_bib128","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41379-019-0310-0","article-title":"MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma","volume":"33","author":"Chapel","year":"2020","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.prp.2024.155276_bib129","doi-asserted-by":"crossref","first-page":"313","DOI":"10.5858\/arpa.2021-0331-OA","article-title":"A Combination of MTAP and p16 immunohistochemistry can substitute for CDKN2A Fluorescence in situ hybridization in diagnosis and prognosis of pleural mesotheliomas","volume":"147","author":"Brcic","year":"2023","journal-title":"Arch. Pathol. Lab Med"},{"key":"10.1016\/j.prp.2024.155276_bib130","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s00424-020-02417-x","article-title":"Glucose transporters in adipose tissue, liver, and skeletal muscle in metabolic health and disease","volume":"472","author":"Chadt","year":"2020","journal-title":"Pflug. Arch."},{"key":"10.1016\/j.prp.2024.155276_bib131","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1080\/1354750X.2020.1714735","article-title":"Diagnostic value of GLUT-1 in distinguishing malignant mesothelioma from reactive mesothelial cells: a meta-analysis","volume":"25","author":"Zhong","year":"2020","journal-title":"Biomarkers"},{"key":"10.1016\/j.prp.2024.155276_bib132","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/cncy.20071","article-title":"The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions","volume":"118","author":"Hasteh","year":"2010","journal-title":"Cancer Cytopathol."},{"key":"10.1016\/j.prp.2024.155276_bib133","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/00000478-198601000-00005","article-title":"Reactive and neoplastic serosal tissue","volume":"10","author":"Bolen","year":"1986","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.prp.2024.155276_bib134","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/00129039-200206000-00014","article-title":"Diagnostic Use of muscle markers in the cytologic evaluation of serous fluids","volume":"10","author":"Afify","year":"2002","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"10.1016\/j.prp.2024.155276_bib135","doi-asserted-by":"crossref","first-page":"108","DOI":"10.5606\/tgkdc.dergisi.2016.11606","article-title":"Epithelial membrane antigen in differential diagnosis of malignant mesothelioma, metastatic adenocarcinoma, and reactive mesothelial hyperplasia","volume":"24","author":"Arslan","year":"2016","journal-title":"Turk. J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.prp.2024.155276_bib136","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nm.1918","article-title":"Regulation of cardiovascular development and integrity by the heart of glass\u2013cerebral cavernous malformation protein pathway","volume":"15","author":"Kleaveland","year":"2009","journal-title":"Nat. Med."},{"key":"10.1016\/j.prp.2024.155276_bib137","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.3390\/cancers15051537","article-title":"Benefits and challenges of inhibiting EZH2 in malignant pleural mesothelioma","volume":"15","author":"Al Khatib","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2024.155276_bib138","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/modpathol.3880483","article-title":"Expression of Cytokeratin 5\/6 in Epithelial Neoplasms: An Immunohistochemical Study of 509 Cases","volume":"15","author":"Chu","year":"2002","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.prp.2024.155276_bib139","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5858\/arpa.2017-0124-RA","article-title":"Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group","volume":"142","author":"Aliya Noor Husain","year":"2018","journal-title":"Arch. Pathol. Lab Med."},{"key":"10.1016\/j.prp.2024.155276_bib140","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1365-2559.2005.02098.x","article-title":"Expression of D2-40 in lymphatic endothelium of normal tissues and in vascular tumours","volume":"46","author":"Fukunaga","year":"2005","journal-title":"Histopathology"},{"key":"10.1016\/j.prp.2024.155276_bib141","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/modpathol.3800749","article-title":"D2-40 immunohistochemistry in the differential diagnosis of seminoma and embryonal carcinoma: a comparative immunohistochemical study with KIT (CD117) and CD30","volume":"20","author":"Lau","year":"2007","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.prp.2024.155276_bib142","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920950207","article-title":"Pulmonary sarcomatoid carcinoma: progress, treatment and expectations","volume":"12","author":"Li","year":"2020","journal-title":"Ther. Adv. Med. Oncol."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033824001870?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033824001870?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T17:47:06Z","timestamp":1716400026000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033824001870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":142,"alternative-id":["S0344033824001870"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2024.155276","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnostic performance of immunohistochemistry markers for malignant pleural mesothelioma diagnosis and subtypes. A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2024.155276","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier GmbH. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"155276"}}